The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
=== June === 1 June – A bioRxiv preprint reports the first use of base editing to alter the genome of early human embryos. Researchers at Columbia University used the technique to introduce precise single-letter DNA changes without the large chromosomal alterations previously associated with double-strand-break CRISPR gene editing, while noting that the approach remains far from clinical use and raises ethical questions over human germline engineering. 3 June – A report by the United Nations University Institute for Water, Environment and Health estimates that global data centre electricity consumption could reach 945 TWh by 2030, driven partly by growing demand for artificial intelligence, with associated water use rising to 9.3 trillion litres and carbon dioxide emissions to 399 million tonnes. 4 June – Chinese researchers discover the two-state model of liquid water theorizing that water is composed of two distinct and interconvertible local structures at the high and low density phase boundary. 5 June – Researchers at the University of Cambridge and DIOSynVax report the first human clinical trial of a vaccine whose active component was designed entirely by computer simulations. The candidate pan-Sarbecovirus vaccine, pEVAC-PS, uses a machine-learning-designed "super-antigen"; a phase I trial in 39 healthy volunteers finds it safe and able to trigger immune responses to SARS-CoV-2, SARS-CoV-1, and related bat coronaviruses.
== Committees == CLSI documents are developed by committees consisting of experts in medical testing or related aspects. Each CLSI committee produces consensus documents related to a specific discipline.
In solid phase peptide synthesis, a linker is a molecule that connects the solid phase (a beaded resin support) to the growing peptide chain. The linker is often permanently attached to the solid phase, but carries a transient covalent bond to the peptide (typically its C-terminus) that can be cleaved after completion of the synthesis to release the peptide. Cleavage can take place under various conditions depending on the linker type and result in different C-terminal functionalities of the released peptide, e.g. amides, carboxylic acids, esters, lactams, etc. Linkers that do not attach via the C-terminus do also exist.
== Sclera in animals == The cooperative eye hypothesis suggests that the pale sclera evolved as a method of nonverbal communication that makes it easier for one individual to identify where another individual is looking. In addition to this, the "cooperative eye hypothesis" expands on the proposal that white sclera are a sign of good health, being useful for mate selection. However, the cooperative eye hypothesis has been questioned based on correspondence between known eye gaze following certain behaviors like the stare-in-the-crowd effect and depigmentation patterns. There is also evidence to suggest that eye visibility promotes altruistic behavior by letting others know they are being watched. Animal researchers have found that, in the course of their domestication, dogs have also developed the ability to pick up visual cues from the eyes of humans. Dogs do not seem to use this form of communication with one another and only look for visual information from the eyes of humans. Chimpanzees have also been found to be able to discern gaze direction in humans, and are the only other animals found to do this thus far. Other mammals with white or pale sclera include chimpanzees, many orangutans, some gorillas, and bonobos. The eyes of all non-human primates have been thought to be dark with small, barely visible sclera, but recent research has suggested that white sclera are not uncommon in chimpanzees, and are also present in other mammals. Most non-human mammals are thought to have a darker sclera which conceals gaze direction.
Sources: en.wikipedia.org
Although the term was coined in the late 1980s one of the first retroactively recognized examples of a killer application is the VisiCalc spreadsheet, released in 1979 for the Apple II. Because it was not released for other computers for 12 months, people spent US$100 (equivalent to $400 in 2025) for the software first, then $2,000 to $10,000 (equivalent to $9,000 to $44,000) on the requisite Apple II. Byte wrote in 1980, "VisiCalc is the first program available on a microcomputer that has been responsible for sales of entire systems", and Creative Computing's VisiCalc review is subtitled "reason enough for owning a computer". Others also chose to develop software, such as EasyWriter, for the Apple II first because of its higher sales, helping Apple defeat rivals Commodore International and Tandy Corporation. The co-creator of WordStar, Seymour Rubinstein, argued that the honor of the first killer app should go to that popular word processor, given that it came out a year before VisiCalc and that it gave a reason for people to buy a computer. However, whereas WordStar could be considered an incremental improvement (albeit a large one) over smart typewriters like the IBM Electronic Selectric Composer, VisiCalc, with its ability to instantly recalculate rows and columns, introduced an entirely new paradigm and capability unavailable on larger computers. Lotus 1-2-3 similarly benefited sales of the IBM PC. Noting that computer purchasers did not want PC compatibility as much as compatibility with certain PC software, InfoWorld suggested "let's tell it like it is.
In the 1950s–1960s, freeze drying began to be viewed as a multi-purpose tool for both pharmaceuticals and food processing. In 2020, freeze dried candy saw a major surge in popularity in the USA due to viral popularity on social media with freeze dried versions of popular candies such as Skittles, Nerd Gummy Clusters, and SweeTarts appearing in stores.
Her testimony contributed to UN Security Council sanctions being imposed on two Houthi security officials in February 2021. It was later alleged that she admitted some of her testimony was untrue, and she had embellished claims at the request of Saudi officials.
Sources: en.wikipedia.org
== History == The condition was first described in 1561 in correspondence between Andreas Vesalius and Gabriele Falloppio and separately by Gabriele Falloppio. The condition is named after François Gigot de la Peyronie, who described it in 1743. Peyronie was the personal physician of King Louis XV and cofounder of the Académie Royale de Chirurgie, which was later included in the French Académie nationale de médecine.
In 2015, in the Journal of Molluscan Studies, Puillandre, Duda, Meyer, Olivera & Bouchet presented a new classification for the old genus Conus. Using 329 species, the authors carried out molecular phylogenetic analyses. The results suggested that the authors should place all cone snails in a single family, Conidae, containing four genera: Conus, Conasprella, Profundiconus and Californiconus. The authors group 85% of all known cone snail species under Conus. They recognize 57 subgenera within Conus, and 11 subgenera within the genus Conasprella.
==== Jasmine ==== Marika Reimon (礼紋 茉莉花, Reimon Marika), also known as "Jasmine" (ジャスミン, Jasumin), is a calm and collected psychic, or "ESPer", who serves as Deka Yellow (デカイエロー, Deka Ierō). In the past, she suffered from depression over her then-inability to control her abilities and contemplated suicide by allowing an Alienizer to kill her. However, she was rescued and recruited by Doggie Kruger. In the present, she is good friends with her teammate Umeko, with whom she forms a tag-team called the Twin Cam Angels (ツインカム・エンジェル, Tsuin Kamu Enjeru). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Jasmine is married and has a son named Taiga (大我). Jasmine's ESPer abilities allow her to pick up on sensory impressions of others by handling an object connected to them or visiting a location her target has been to, though overuse of her powers exhausts her. To control her powers, she wears gloves. Furthermore, as a result of breast-feeding her son during the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Jasmine temporarily gained the ability to teleport herself to any part of the universe, which she loses as of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. In the crossover film Mahō Sentai Magiranger vs. Dekaranger, she displays the ability to break the fourth wall.
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.